

**Iowa Medicaid Pharmaceutical and Therapeutics Committee
Minutes**

Date: November 12, 2009

Chair: Susan Purcell, R.Ph.

Time: 8:32 a.m. to 2:15 p.m.

Location: Capitol Room 116, Des Moines, Iowa

Committee Members Present: Bruce Alexander, R.Ph., Pharm.D., BCPP; Matthew Osterhaus, R.Ph.; Susan Purcell, R.Ph, CGP; Hayley L. Harvey, DDS, MS; Mary Larew, M.D. (who left at 1:00); Charles Wadle, D.O.; and Carole Frier, D.O.

Iowa DHS Staff Present: Susan Parker, Pharm.D., Pharmacy Consultant; and Brad Horn (Assistant District Attorney (for the afternoon session only).

Iowa Medicaid Enterprise (IME) Staff Present: Tim Clifford, M.D.; John Grotton, R.Ph.; Sandy Pranger, R.Ph.; Erin Halverson, R.Ph.; and Melissa Biddle.

Chairperson Sue Purcell called the meeting to order.

- I. Sue Purcell asked that each committee, DHS staff, and IME staff member introduce themselves to the public. The September 10, 2009 open session minutes were reviewed. Matt Osterhaus made the motion to approve the minutes. Bruce Alexander seconded the motion. The motion passed with no objections.
- II. PDL (Dr. Clifford): There will be 5 significant upcoming changes that will create a significant amount of savings for the State and/or displace many members from one drug to go onto another.
- III. Drug Rebate Issues: The Healthcare Reform Bill, in which the minimum CMS rebate will be increased 5 points from 15% of AMP, has the potential to affect all CMS rebates, if approved by both the House of Representatives and the Senate.
- IV. PA Criteria/Pro-DUR Edits (Susan Parker): Informational Letter 842 addressed Synagis coverage for the 2009-2010 RSV season, new PA criteria for febuxostat and thrombopoietin receptor agonists, noncoverage of Prilosec OTC effective November 1, 2009, and coverage of Prevacid SoluTabs. The November 5th letter to DHS from the DUR Commission addressed PA recommendations for Ketorolac, Muscle Relaxants, Antihistamines, and Fentanyl Short-Acting Oral Products.
- V. Legislation: None at this time.
- VI. IME Updates: To meet the Governor's budget cut expectation, a request was made to remove the exclusion for mental health drugs from the PDL, but the request was denied.

The remaining budget changes in regards to the PDL recommended by the IME will result in \$233,000 in savings for the State. These changes include: lowering the dispensing fee to \$4.34, as well as removing the 30-day non-preferred drug override (the 72-hour override will still be an option). A P&T listserv has now been developed; anyone wanting information about the P&T meeting can sign up to receive emails on the website www.iowamedicaidpdl.com. Emails will be sent out containing the same information (agendas, reports, drug monographs, etc.) as what is currently posted on the site.

VII. The public speakers were:

| <u>SPEAKER</u> | <u>SUBJECT</u> |
|--|---|
| Louis Gerbino, M.D. | FazaClo |
| Deb Parker, FNP-BC | Veramyst |
| Laura Delaney, PA-C | Veramyst |
| Jason Ekwena, M.D. from City Family Clinic | Veramyst |
| Andrew Korotzer from Strativa | Generic substitution of Anti-epileptics |
| Denise Mervis from Gilead Sciences | Ranexa and Letairis |
| Ndidi Yaucher from Novartis | Tekturna and Tekturna HCT |
| Michael Widlowski from Sandoz | Omnitrope |
| Lisa Pulkrabek from Astellas | Protopic |
| Leslie Meinert from Merck | Januvia and Janumet |
| Eric Cox from Amylin | Byetta |
| Edward Grotjan from Shire | Lialda |
| Jodi Jensen from UCB, Inc. | Vimpat |
| Fran Gander from Novo Nordisk | Norditropin |
| Tom Westenberger from King Pharmaceuticals | Embeda |
| Theodore Darkow from Bristol-Myers Squibb | Onglyza |
| Rob Pearson from GlaxoSmithKline | Avandia and Veramyst |
| Teresa Bomhoff, National Alliance on Mental Illness of Greater Des Moines | Open access for mental health drugs |
| John Kroeten from Boehringer-Ingelheim | Micardis |
| Tommy Brock from United Therapeutics | Adcirca |
| Jennifer Stoffel from Ortho McNeil Janssen | Invega Sustenna |
| Maureen Kubacki from Centocor Ortho Biotech | Simponi |
| Frank Burns from Pfizer | Caduet |

At 10:18, motion to go to closed session was made by Hayley Harvey and seconded by Carole Frier. The motion passed with unanimous approval. Open session resumed at 12:50.

VIII. PDL Discussion and Deliberation (Dr. Clifford): It was recommended to change Twinject to preferred. The following were recommended to be non-preferred: Avandaryl, Actos 30mg and 45mg, Avandia, Duetact, Actoplus Met, Avandamet, and Veramyst. It was recommended to grandfather existing users of the Avandia products (Avandia, Avandamet, Avandaryl, and Duetact) which have previously tried Actos or have a congestive heart failure diagnosis. Additionally, it was recommended to change Advair Diskus 100/50, 250/50, and 500/50 (package size 14 only) and Spiriva Handihaler (package size 5 only) to non-preferred. Serevent Inhaler and Azmacort will be removed from the PDL since they have been discontinued by the

manufacturer. Also, it was recommended to keep Actos 15mg preferred and remove the current quantity limit to allow for the use of multiple 15mg tablets. Carole Frier motioned to accept the above recommendations. Chuck Wadle seconded, and the motion passed with all members in favor. (Mary Larew was present for this vote, but left directly thereafter.) It was then recommended to change topiramate to preferred. Matt Osterhaus motioned to accept, and Bruce Alexander seconded. The motion passed unanimously. Carole Frier moved that all members with epilepsy be allowed to have non-preferred brand-name anticonvulsants upon submission of a PA form from a neurologist. However, allowing this might pose an issue with the Federal Upper Limit (FUL) program. Dr. Clifford will run an analysis on the possible impact to the drug budget and aggregate FUL cap, and bring that report to the March meeting. Venlafaxine ER and bupropion XL will be preferred, while Wellbutrin XL, Effexor XR, Tofranil PM, and imipramine pamoate will all become non-preferred. Hayley Harvey motioned to accept these recommendations, with the caveat (as Matt Osterhaus had suggested in prior discussion) that Wellbutrin XL and Effexor XR will remain preferred until March 1, 2010 so that pharmacies could clean out their inventories beforehand. (Existing users would be grandfathered, but all new starters would have to receive the generic.) Matt Osterhaus seconded, and the motion passed with no objections. It was recommended to change Fazaclo to non-preferred and grandfather existing users. Carole Frier motioned to accept this, and Chuck Wadle seconded. The motion passed unanimously. Augmentin XR, Caduet, Omnicef, and Suprax will be changed to non-preferred. Also, Ortho Novum 10/11 will be removed from the PDL since it has been discontinued by the manufacturer; thus, the generic, norethindrone-ethinyl estradiol tab, will become preferred. Additionally, it was recommended to remove Vantin Suspension and Vantin 100mg Tablets from the PDL since they have also been discontinued by the manufacturer. LoSeasonique and Seasonique will become preferred. Hayley Harvey motioned to accept these recommendations, Carole Frier seconded, and the motion passed unanimously. Opium Tincture, Floxin Otic, and Floxin Otic Singles will change to non-preferred, and the generic ofloxacin otic will change to preferred. Creon will be preferred with conditions. It was recommended to change ranitidine syrup and Apriso to preferred, and Zantac Syrup (effective March 1, 2010), Pentasa 500mg, and Lialda to non-preferred. Matt Osterhaus motioned to accept these changes. Bruce Alexander seconded, and the motion passed with no objections or abstentions. Cimzia Kit and Omnitrope will be changed to preferred with conditions. Zegerid will be removed from the PDL because it no longer has a signed rebate agreement with CMS. It was recommended to change Peg-Intron, Peg-Intron Redipen, and Peg-Intron Redipen Pak 4 to non-preferred. Existing users would be grandfathered. Rebetol will become non-preferred and ribavirin 200mg capsules preferred. Sue Purcell motioned to accept these recommendations. Hayley Harvey seconded, and the motion passed unanimously. Acyclovir 200mg/5ml Suspension will become preferred due to availability issues with the preferred brand (Zovirax Suspension). It was recommended to add Humalog Mix 50/50 as preferred, and Humalog Pen and Humalog Mix 50/50 Pen as preferred with conditions. Novolin R InnoLet, Novolin N InnoLet, and Novolin 70/30 InnoLet will be removed from the PDL since they have been discontinued by the manufacturer. Additionally, Novolin R PenFill, Novolin N PenFill, and Novolin 70/30 PenFill will be removed from the PDL for this same reason. Sue Purcell motioned to accept these recommendations. Chuck Wadle seconded, and the decision was unanimous. Imitrex, Relpax, and Treximet will become non-preferred with conditions, and sumatriptan preferred with conditions. Chuck Wadle motioned to accept these recommendations, and Bruce Alexander seconded. The motion passed with no objections or

abstentions. It was recommended to add OTC Calcium Carbonate Chew Tablet 500mg, 750mg, and 1000mg as preferred with conditions. OTC Calcium Carbonate-Vitamin D Tablet 600mg-400unit will also be preferred with conditions. Additionally, Kadian 80mg and 200mg will become non-preferred. Carole Frier motioned to accept these recommendations, and Bruce Alexander seconded. The motion passed unanimously. It was recommended to remove Zaditor from the PDL as it is only available as an OTC product, and change Combigan, Acular PF, and Zymar to preferred. Dr. Clifford recommended brand ophthalmic fluoroquinolone products be non-preferred for pediatric patients. Bruce Alexander motioned to accept these recommendations. Chuck Wadle seconded, and the motion passed with all in favor. It was recommended to change Fosamax Plus D to non-preferred, Fortical to preferred, Letairis to preferred with conditions, and Solaraze to non-preferred. Matt Osterhaus motioned to accept these recommendations. Chuck Wadle seconded, and the motion passed unanimously.

- IX. RDL Discussion and Deliberation: It was recommended to change midazolam injection to non-preferred, Casodex to non-recommended (and require a Select Brand Name Drug PA Form), and bicalutamide to recommended. Sue Purcell motioned to accept these recommendations, and Hayley Harvey seconded. The motion passed with no objections or abstentions.
- X. Newly Released Drugs: It was recommended to make: Adcirca non-preferred with conditions, Besivance non-preferred, Effient non-preferred, Intelence non-recommended, Multaq preferred, and Onglyza non-preferred. Bruce Alexander motioned to accept these recommendations, and Hayley Harvey seconded. The motion passed unanimously.
- XI. Newly Released Generic Drugs, New Dosage Forms, New Drug Names, and New Strengths: The following were recommended to be non-preferred: calcipotriene, calcium acetate, nateglinide, protriptyline (also making Vivactil non-preferred), norgestimate-eth estradiol tab (Tri-Lo Sprintec), Colcrys, Embeda, Extavia, Acuvail 0.45%, and Asacol HD 800mg. Leuprolide, melphalan injection, and tacrolimus will be non-recommended. Finally, the following were recommended to be non-preferred with conditions: clindamycin/benzoyl peroxide gel, dexmethylphenidate, Edluar Sublingual Tablets, Onsolis Buccal Film, Tyvaso Inhalation Solution, Epiduo, Astepro 0.15% Spray, and Zipsor 25mg Capsule (and make diclofenac potassium 50mg tablets preferred). Invega Sustenna Injection will also be non-preferred with conditions. Regarding this status decision, Dr. Clifford said "Financially, we talked about this, and it is on my homework list to see if we can get a contract on Invega Sustenna guaranteeing that its net price to Medicaid will not exceed that of Risperdal Consta." Bruce Alexander thought this comparison should be to risperidone consta and not to the tablets. Dr. Clifford said that both comparisons will be brought back to the committee. Matt Osterhaus motioned to accept these recommendations, and Carole Frier seconded. The motion passed unanimously.

A motion was made by Chuck Wadle to adjourn the meeting. Hayley Harvey seconded the motion. All in attendance approved. The meeting adjourned at 2:15 p.m. The next scheduled meeting will be March 11, 2010.